A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTIN-METHYL-D ASPARTIC ACID RECEPTOR (NMDAR) OR ANTILEUCINE-RICH GLIOMA-INACTIVATED 1 (LGI1) ENCEPHALITIS
Details
Age
Child to Adult
Type of Study
Treatment
Locations
CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Amanda Piquet, MD
Study ID
Protocol Number: 22-0449
More information available at ClinicalTrials.gov: NCT05503264
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers